Several noncardiovascular drugs have the potential to induce Torsades de Pointes cardiac arrhythmias via blockade of the rapid component of the cardiac delayed rectifier K 1 current (I Kr ), which is encoded by human ether-à -go-go-related gene (hERG). The aim of the present study was to characterize possible interactions between terfenadine, binding to a site located inside the central cavity, and the following substances with various binding sites: dofetilide, fluvoxamine, chlorobutanol, and a hERG-specific toxin isolated from scorpion venom (CnErg1). The whole-cell configuration of the patch-clamp technique was employed on hERG channels stably expressed in human embryonic kidney 293 cells. Terfenadine does not interact with dofetilide or fluvoxamine at hERG channels. Slight subadditive inhibitory effects on hERG peak tail currents were observed when terfenadine and CnErg1 were administered in combination. Terfenadine and chlorobutanol synergistically inhibit hERG peak tail currents and enhance each other's inhibitory effect in a concentration-dependent way. In conclusion, terfenadine interacts with CnErg1 and chlorobutanol, but not with dofetilide or fluvoxamine, at hERG channels. It is shown that interactions between chlorobutanol and a hERG channel blocker binding inside the central cavity (terfenadine) produce synergistic effects on hERG currents.
Torsades de Pointes (TdP), a life-threatening form of ventricular arrhythmia, occurs under conditions where cardiac repolarization is delayed (as indicated by prolonged QT intervals from electrocardiographic recordings). A likely mechanism of QT interval prolongation and TdP is blockade of the rapid component of the cardiac delayed rectifier K þ current (I Kr ; review in Keating and Sanguinetti, 1996) . The K v 11.1 protein a-subunit that underlies the I Kr in the heart is encoded by hERG (human ether-à-go-go-related gene) (Sanguinetti et al., 1995; Trudeau et al., 1995; Warmke and Ganetzky, 1994) .
Several noncardiovascular drugs have the potential to induce QT interval prolongations or TdP arrhythmias. Approximately 2-3% of all prescriptions are estimated to involve medications that may unintentionally cause the long QT syndrome (review in Recanatini et al., 2005) . Most of these torsadogenic drugs block hERG currents. Hence, hERG channel blockade is an important indicator of potential proarrhythmic activity (review in Redfern et al., 2003) . Therefore, the International Conference on Harmonization S7B Guideline (CPMP/ICH/423/02) (2005) makes hERG current blockade studies mandatory in drug development. The nonclinical tests required there for assessing the potential of a test substance to delay ventricular repolarization are major hurdles in drug development.
hERG channels have a unique structure, which makes them the binding target for many structurally diverse compounds. Sanguinetti's group used an Ala-scanning mutagenesis approach to identify the amino acid residues, which are crucial for the interactions of the nonsedating H 1 -histamine receptor antagonist, terfenadine, the gastroprokinetic drug, cisapride, and the methanesulfonanilide agent, MK-499, at hERG channels (Mitcheson et al., 2000) . The authors employed a homology model using the bacterial KcsA channel as a template demonstrating that the high-affinity-binding site of terfenadine is located in the central cavity of the channel between the selectivity filter and the activation gate, at Tyr652 and Phe656 in the S6 domain. Recently, also Thr623 and Ser624, located on the base of the pore helix, were shown to interact with terfenadine (Kamiya et al., 2008) .
The terfenadine-binding site overlaps with that of dofetilide, a methanesulfonanilide class III antiarrhythmic drug, which binds to Tyr652 and Phe656 and also to other amino acids Thr623, Ser624, and Val625 located on the base of the pore helix and Gly648 and Val659 in S6 of the hERG channel subunit (Lees-Miller et al., 2000; Kamiya et al., 2006; reviews in Stansfeld et al., 2007, and in Thai and Ecker, 2007) .
However, not all hERG channel blockers bind inside the central cavity (review in Zünkler, 2006) . For the first time, Milnes et al. (2003) identified a drug with hERG channel block properties that are relatively insensitive to mutations of Tyr652 and Phe656, the selective serotonin reuptake inhibitor fluvoxamine. The rapid onset of hERG current block by fluvoxamine seemed to be consistent with binding to an extracellular site, possibly at the outer mouth of the channel (commentary in Mitcheson, 2003) .
Binding sites at the outer mouth of the channel have been identified for hERG-specific toxins found in scorpion venom (ergtoxin-like peptides, e.g., CnErg1, isolated from scorpions of the genus Centruroides; Gurrola et al., 1999) . hERG channels possess an unusually long S5-P linker (43 amino acids in comparison with 12-23 residues in other K v channels), which presumably forms an amphipathic a-helix, which, together with the P-S6 linker, is responsible for a hydrophobic CnErg1-binding site (Gurrola et al., 1999; Pardo-Lopez et al., 2002; reviews in Korolkova et al., 2004, and Restano-Cassulini, 2007) .
Chlorobutanol, which is used as a preservative in parenteral formulations, inhibits hERG currents at millimolar concentrations (Kornick et al., 2003) . Its binding site on hERG channels is unknown. Since it has a much lower affinity to hERG channels than the blockers binding inside the central cavity, it might be suggested that chlorobutanol inhibits hERG currents via interaction with another binding site.
The existence of different binding sites raises the question whether these binding sites interact. If so, how does this influence the effects of simultaneously administered drugs acting at different binding sites. This has been investigated for methadone and chlorobutanol, each inhibiting hERG currents in a concentration-dependent manner; moreover, chlorobutanol enhances the ability of methadone to block hERG currents (Kornick et al., 2003) . Some opioid agonists (L-a-acetylmethadol (levacetylmethadol, LAAM) and methadone) are inhibitors of hERG currents (Katchman et al., 2002) , but their binding sites are not yet known.
The aim of the present study was to characterize possible interactions at hERG channels between a blocker binding inside the central cavity (terfenadine) and substances with various binding sites (dofetilide, fluvoxamine, CnErg1, and chlorobutanol).
MATERIALS AND METHODS
Culture of human embryonic kidney 293 cells stably transfected with hERG channels. Human embryonic kidney (HEK) 293 cells stably expressing hERG channels were kindly provided by Prof C. January (University of Wisconsin). HEK 293 cells were plated at a density of 11 3 10 5 cells per dish (35-mm diameter) and cultured (at 10% CO 2 ) in Dulbecco's modified Eagle's medium with 1 g/l glucose supplemented with 10% fetal calf serum, 100 U/ml penicillin, 100 lg/ml streptomycin, and 2mM glutamine.
Electrophysiological recording. hERG currents were recorded using the whole-cell patch-clamp configuration (Hamill et al., 1981) and an EPC 10 patch clamp amplifier (Heka Elektronik, Lambrecht, Germany). Patch pipettes were pulled from borosilicate glass capillaries (Hilgenberg, Malsfeld, Germany) and had resistances between 3 and 5 MX when filled with pipette solution B (see section Drugs and solutions). Stimulation protocols and data acquisition were carried out using Pulsefit software (Heka Elektronik). The current sample frequency was 1 kHz. At least 50% series resistance compensation was achieved in all experiments. Outward currents flowing from the pipette to the bath solution are indicated by upward deflections. Experiments were performed at room temperature (20-22°C). The bath had a volume of 1 ml and was perfused at a rate of 2 ml/min; about 0.5 min was needed for the exchange of the bath solution.
Determination of the inhibitory effects of test substances on hERG currents was based on the following voltage-clamp protocol: a holding potential of À80 mV and a voltage step to þ 20 mV applied for 2 s to evoke hERG currents, followed by a repolarization step to À40 mV for 2 s to induce hERG tail currents (stimulation frequency of 0.1 Hz). hERG tail currents were leak corrected. Deactivating tail currents were fitted with two exponential functions and extrapolated to the beginning of the repolarization step in order to calculate the peak tail current amplitude.
The voltage dependence of hERG channel activation was determined from peak tail currents measured at À40 mV following 2-s depolarizations to membrane voltages ranging from À40 to þ 40 mV in 10 mV steps. Peak tail current amplitudes were normalized to the maximum peak tail current amplitudes. The voltage dependence of channel availability was determined by fitting the values of the normalized peak tail currents with a Boltzmann equation of the form:
where I was the peak tail current amplitude following the test potential V m , I max was the maximal peak tail current amplitude, V ½ was the potential at which channels were half-maximally activated, and k was the slope factor describing channel activation. The time dependence of hERG current blockade by terfenadine, chlorobutanol, and the terfenadine and chlorobutanol combination was evaluated by using three different voltage protocols. First, an envelope of tails protocol: cells were held at À80 mV and stepped to þ 40 mV for 50-600 ms in 50-ms increments; peak tail currents after repolarization to À40 mV at each time point were measured as described above in the absence (control) and presence of test substances. Second, a long step pulse protocol: HEK 293 cells were stepped from a holding potential of À80 mV to þ 20 mV for 10 s; stimulation was terminated and test substances were applied for > 5 min; and then the voltage protocol was applied again. Third, development and recovery of block were determined by applying 2-s voltage steps to þ 20 mV from a holding potential of À80 mV, followed by 2-s repolarization steps to À40 mV at a stimulation frequency of 0.1 Hz; peak tail currents were determined during the application of test substances until steady-state block was achieved and during the 10-min washout of test substances.
Data analysis and statistical procedures. The concentration-response relationships for the inhibition of peak tail current amplitudes by test substances were calculated according to the logistic form of the Hill equation:
where I c is the peak tail current amplitude during the control periods before application of the test substances and I is the peak tail current amplitude in the presence of test substances, a is the fraction of the hERG peak tail current sensitive to inhibition by the test substance (a measure of the intrinsic activity; this value was set to 1 in the case of terfenadine, dofetilide, fluvoxamine, and chlorobutanol since these substances inhibit hERG currents completely), n is the slope parameter (Hill coefficient), x is the concentration of test substances, and K (¼ IC 50 ) is the midpoint of the curve with px ¼ Àlogx and pK ¼ ÀlogIC 50 . For calculation of the concentration-response relationships for the inhibition of hERG peak tail current amplitudes, the test substances were applied cumulatively at increasing concentrations and studied at the following concentrations: 3, 10, 30, 100, and 300nM terfenadine; 1, 3, 10, 30, and 100nM dofetilide; 0.3, 1, 3, 10, and 30lM fluvoxamine; 0.3, 1, 3, 10, and 30mM chlorobutanol; 0.3, 1, 3, 10, 30, and 100nM CnErg1. The number of observations ranged from 3 to 12 per test concentration.
The combined effects of two substances A and B in the case of additivity were calculated according to van den Brink (1977) :
where I c is the hERG peak tail current amplitude during the control periods before application of the test substances and I AB is the hERG peak tail current amplitude in the presence of the test substances, A and B, applied in combination, a and b are the intrinsic activities, and IC 50A and IC 50B are the half-maximally inhibitory concentrations of A and B.
According to the diagonal constant ratio combination design proposed by Chou (2006) , the combination ratio of two test substances applied simultaneously was kept at an equipotency ratio (IC 50 ratio) since the contribution of each test substance to the combination is approximately equal under these conditions. The combination index (CI) for the quantification of synergism or antagonism for two test substances administered simultaneously was calculated according to Chou (2006) :
where the denominators A (x)1 and B (x)1 stand for the concentrations of test substances A and B, with each inhibiting hERG peak tail currents by x%, and the numerators A 1 and B 1 in combination also inhibit hERG peak tail currents by x%. The A (x)1 and B (x)1 values were calculated from Equation 2. A CI equaling 1 indicates additivity, a CI smaller than 1 indicates synergism, and a CI greater than 1 indicates antagonism. The results are expressed as means with the 95% confidence intervals given in parentheses. Equations were fitted using the Sigma Plot Windows program (Jandel Scientific). Significances were calculated by the two-tailed nonpaired ttest for single comparisons and by ANOVA with Bonferroni correction for multiple comparisons. p < 0.05 was considered to be significant. ] ¼ 0.7mM). Terfenadine and fluvoxamine were purchased from Sigma (St Louis, MO), dofetilide from Sequoia (Pangbourne, UK), and CnErg1 from Alomone Labs (Jerusalem, Israel). Stock solutions of 30mM terfenadine and 3mM dofetilide were prepared in dimethylsulfoxide and stock solutions of 30mM fluvoxamine, 30mM chlorobutanol, and 1lM CnErg1 in solution A. Table 1 shows the IC 50 values, Hill coefficients (n), and intrinsic activities (a) calculated for the concentrationdependent inhibition of hERG peak tail currents by terfenadine, dofetilide, fluvoxamine, chlorobutanol, and CnErg1. Figure 1 shows representative experiments demonstrating the effects of the combined administration of terfenadine with high-affinity These values were fixed to 1.
RESULTS

FIG. 1.
Effects on hERG currents of terfenadine combined with dofetilide, fluvoxamine, chlorobutanol, or CnErg1, each tested at half of their respective IC 50 values. The voltage protocol is shown above. Arrows indicate zero current levels. The block of hERG peak tail currents is 38.6% at 13.8nM terfenadine þ 6.5nM dofetilide, 41.2% at 13.8nM terfenadine þ 1.8lM fluvoxamine, 62.7% at 13.8nM terfenadine þ 3.7mM chlorobutanol, and 30.7% at 13.8nM terfenadine þ 3.2nM CnErg1.
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FRIEMEL AND ZÜ NKLER hERG channel blockers with IC 50 values in the nanomolar concentration range (dofetilide and CnErg1), a low-affinity hERG channel blocker with an IC 50 value in the micromolar concentration range (fluvoxamine), or a very low-affinity hERG channel blocker with an IC 50 value in the millimolar concentration range (chlorobutanol) on hERG peak tail currents. The results of several experiments are summarized in Table 2 . The inhibitory effects of combinations of terfenadine with dofetilide or fluvoxamine on hERG peak tail currents did not deviate markedly from the expected values in cases of additivity (Fig. 1, Table 2 ). The combination of terfenadine and CnErg1 had subadditive inhibitory effects on hERG peak tail currents at low concentrations ( Table 2 ). The interaction between terfenadine and CnErg1 was studied in detail, and CI values were calculated according to Chou (2006) : CI values of 0.9-1.1 indicate nearly additive effects of a combination of test substances; 1.10-1.20, 1.20-1.45, and > 1.45 indicate slight antagonism, moderate antagonism, and antagonism, respectively; 0.85-0.9, 0.7-0.85, 0.3-0.7, 0.1-0.3, and < 0.1 indicate slight synergism, moderate synergism, synergism, strong synergism, and very strong synergism, respectively. When hERG peak tail currents were halfmaximally preblocked by terfenadine and CnErg1 at the increasing concentrations of 1, 3, and 10nM was administered simultaneously, the calculated CI values were 1.13 (n ¼ 6), 1.11 (n ¼ 7), and 0.83 (n ¼ 5), respectively, indicating additive effects on hERG channels; by contrast, when first CnErg1 was administered and then terfenadine at increasing concentrations of 1, 3, and 10nM was administered simultaneously, the calculated CI values were 1.23 (n ¼ 5), 1.46 (n ¼ 5), and 1.20 (n ¼ 7), respectively, indicating subadditive effects. The effects of the combination of terfenadine and chlorobutanol on hERG peak tail currents showed superadditivity at high concentrations (Fig. 1, Table 2 ). These interactions between terfenadine and chlorobutanol on hERG channels were examined in detail (Fig. 2) . hERG currents were preblocked by chlorobutanol at Significantly different (p < 0.05) from the expected value in the case of additivity.
FIG. 2.
CI-Fa plot for the effects of terfenadine-chlorobutanol combinations on hERG peak tail current amplitudes. The CI value on the y-axis is plotted as a function of the effect levels (Fa: hERG peak tail current amplitude affected, 1 À I/I c ) on the x-axis. CI < 1, ¼ 1, and > 1 indicate synergism, additive effect, and antagonism, respectively. (A) The CI-Fa plot for the inhibition of hERG peak tail currents by simultaneous administration of 2.5 and 7.4mM chlorobutanol and increasing concentrations (1, 3, 10, 30, and 100nM) of terfenadine. The slopes of the regression lines are À0.62 and À1.35 in the presence of 2.5 and 7.4mM chlorobutanol, respectively, and increasing concentrations of terfenadine. (B) The CI-Fa plot for the inhibition of hERG peak tail currents by simultaneous administration of 9.2 and 27.7nM terfenadine and increasing concentrations (0.1, 0.3, 1, 3, and 10mM) of chlorobutanol. The slopes of the regression lines are À0.86 and À1.54 in the presence of 9.2 and 27.7nM terfenadine, respectively, and increasing concentrations of chlorobutanol. The number of observations was 6-14 per concentration of the combination tested.
INTERACTIONS AT hERG CHANNELS concentrations inhibiting the peak tail currents by 25 or 50% (2.5 and 7.4mM); additionally, terfenadine was administered at increasing concentrations. The slopes of the regression lines of the CI-Fa plot increased with increasing chlorobutanol concentrations (from À0.62 at 2.5mM to À1.35 at 7.4mM chlorobutanol), indicating that chlorobutanol enhanced the inhibitory effects of terfenadine concentration dependently. Similarly, hERG currents were preblocked by terfenadine at concentrations inhibiting the peak tail currents by 25 or 50% (9.2 and 27.7nM); additionally, chlorobutanol was administered at increasing concentrations. The slopes of the regression lines of the CI-Fa plot increased with increasing terfenadine concentrations (from À0.86 at 9.2nM to À1.54 at 27.7nM terfenadine), indicating that terfenadine enhanced the inhibitory effects of chlorobutanol concentration dependently.
In order to further characterize the mechanism of the synergistic effects of terfenadine and chlorobutanol, the voltage-and time-dependent inhibitory effects were studied for separate administration of terfenadine and chlorobutanol at their half-maximally inhibitory concentrations (IC 50 values) of 27.7nM and 7.4mM, respectively, and of the combination at half their IC 50 values (13.8nM and 3.7mM). Block of hERG currents was strongly voltage dependent for chlorobutanol (stronger at more positive membrane potentials), whereas terfenadine-induced block demonstrated only slight voltage dependence. For the combination of terfenadine and chlorobutanol, voltage dependence was intermediate (Fig. 3) . Voltage dependence of steady-state hERG current activation had the following V ½ and k values: 9.1 ± 0.3 mV and 7.7 ± 0.3 mV in the absence of test substances (control; n ¼ 28); 5.7 ± 1.1 mV and 6.8 ± 0.9 mV for terfenadine (n ¼ 8); À15.2 ± 0.6 mV and 8.4 ± 0.5 mV for chlorobutanol (n ¼ 11); and À4.9 ± 0.7 mV and 7.4 ± 0.6 mV for the terfenadine and chlorobutanol combination (n ¼ 9). Chlorobutanol and the terfenadine and chlorobutanol combination induced statistically significant hyperpolarizing shifts in the voltage dependence of channel activation (p < 0.05); the k values did not significantly vary between the different experimental conditions (p > 0.05). The voltage dependence of the effects of chlorobutanol and the terfenadine and chlorobutanol combination coincided with the voltage range over the rising phases of the steady-state activation curves corresponding to the membrane potential ranges over which hERG channel opening occurs (Fig. 3B) .
The time-dependent block by terfenadine, chlorobutanol, and the terfenadine and chlorobutanol combination was first determined by an envelope of tails protocol for the study of the effects of progressive hERG channel activation on current blockade (Fig. 4) . The time dependences of the fractional block of hERG current amplitudes (after depolarization to a membrane voltage of þ 40 mV) by both the chlorobutanol and the terfenadine and chlorobutanol combination were fitted with mono-exponential functions, yielding the following half-life (t ½ ) values for the onset of hERG current blockade: 251 ms for chlorobutanol and 277 ms for the terfenadine and chlorobutanol combination. The terfenadine-induced hERG current block was not significantly different (p > 0.05) at depolarizing pulses between 200 and 600 ms duration.
Second, a long step pulse protocol was used (Fig. 5) . The time dependences of the fractional block of hERG current amplitudes (during the long pulse protocol) by both the chlorobutanol and the terfenadine and chlorobutanol combination were fitted with mono-exponential functions, yielding the following values for t ½ : 1.1 s for chlorobutanol and 1.7 s for the terfenadine and chlorobutanol combination. Terfenadine-induced block increased slightly but not significantly (p > 0.05) between seconds 1 and 10.
Third, when cells were repetitively stimulated at a frequency of 0.1 Hz (Fig. 6) , development of hERG current blockade occurred at t ½ values of 5.4 ± 0.5 min for terfenadine (n ¼ 6), 1.8 ± 0.2 min for chlorobutanol (n ¼ 5), and 4.0 ± 0.8 min for the terfenadine and chlorobutanol combination (n ¼ 7). On washout, the effects of chlorobutanol recovered rapidly with a t ½ value of 1.3 ± 0.3 min. By contrast, the effects of both the terfenadine and the terfenadine and chlorobutanol combination showed poor reversibility after a 10-min washout and the block was still 43.5 ± 4.7% and 29.3 ± 5.2%, respectively, which was not significantly different (p > 0.05).
In order to study the effects of chlorobutanol applied intracellularly, chlorobutanol was added to the pipette solution at a concentration of 7.4mM to diffuse into the cell. Intracellularly applied chlorobutanol had no effects on hERG peak tail current amplitudes, which were 100.8 ± 2.9% (n ¼ 7) of the control 10 min after the whole-cell configuration was established.
DISCUSSION
It is shown in the present study that terfenadine does not interact with dofetilide or fluvoxamine at hERG channels. Slight subadditive inhibitory effects on hERG peak tail currents were observed when terfenadine and CnErg1 were administered in combination. Terfenadine and chlorobutanol in combination inhibited hERG peak tail currents synergistically, and each substance enhanced the inhibitory effect of the other substance in a concentration-dependent manner.
The IC 50 value for block of hERG peak tail currents by terfenadine (27.7nM, Table 1 ) obtained in the present study was slightly lower than the values reported previously (56-204nM; review in Stansfeld et al., 2007) . The lower IC 50 value might be due to the long period of administration of terfenadine (about 5-7 min). The administration was prolonged because of the recent observation (Stork et al., 2007) that at a stimulation frequency of 0.1 Hz, steady-state inhibition of hERG currents by terfenadine is reached after about 5-10 min of drug application. The IC 50 value for block of hERG peak tail currents by dofetilide (12.9nM, Stansfeld et al., 2007) . hERG peak tail currents were blocked by fluvoxamine with an IC 50 value of 3.6lM (Table 1) , thus similar to the previously reported value (3.8lM; Milnes et al., 2003) . Also, the IC 50 value for the block of hERG peak tail currents by chlorobutanol (7.4mM, Table 1 ) is similar to the previously reported value (4.4mM; Kornick et al., 2003) . Fitting the concentration-response relationship for the inhibition of hERG peak tail current amplitudes by chlorobutanol according to Equation 2 yielded a value for a of 1.1 (0.6-1.6), which was not significantly different from unity; therefore, it was assumed that high concentrations of chlorobutanol inhibit hERG currents completely. The value for a was fixed to unity to calculate the IC 50 value and the Hill coefficient given in Table 1 . The scorpion toxin CnErg1 binds to hERG channels with a 1:1 stoichiometry (Gurrola et al., 1999; Hill et al., 2007; Pardo-Lopez et al., 2002) , so that the value for the Hill coefficient was fixed to 1 in order to calculate the concentration-response relationship for the inhibition of hERG peak tail current amplitudes by CnErg1 according to Equation 2. The IC 50 value (6.4nM, Table 1 ) is within the range of the previously reported values (6-16nM; Gurrola et al., 1999; Hill et al., 2007; Pardo-Lopez et al., 2002) . Peptide toxins usually occlude the pore of the channel; however, CnErg1 did not completely inhibit hERG currents at   FIG. 3 . Voltage-dependent modulation of hERG currents by terfenadine, chlorobutanol, and the combination of terfenadine and chlorobutanol. The voltage protocol is shown above. (A) Representative hERG current traces in the absence (control, left traces) and presence of 27.7nM terfenadine (upper traces), 7.4mM chlorobutanol (middle traces), or the combination of 13.8nM terfenadine and 3.7mM chlorobutanol (lower traces). Arrows indicate zero current levels. (B) The normalized Boltzmann functions describing the voltage-dependent activation of hERG currents in the presence of 27.7nM terfenadine, 7.4mM chlorobutanol, and the combination of 13.8nM terfenadine and 3.7mM chlorobutanol and the mean data for the voltage dependence of fractional block of hERG peak tail currents indicated by the bars. Symbols represent means and the vertical lines the SE. The number of experiments was 8 for terfenadine, 11 for chlorobutanol, and 9 for the combination.
INTERACTIONS AT hERG CHANNELS 351 high concentrations (Table 1) , in accordance with previous observations that the maximal effect of CnErg1 is about 90% suppression of the hERG current (Hill et al., 2007; Pardo-Lopez et al., 2002) .
The combination of terfenadine and dofetilide had additive inhibitory effects on hERG peak tail currents (Fig. 1, Table 2 ), which seems to be due to overlapping binding sites in the central cavity of the hERG channel for both terfenadine and dofetilide (Mitcheson et al., 2000; review in Stansfeld et al., 2007) .
The lack of interactions between terfenadine and fluvoxamine (Fig. 1, Table 2 ) was surprising. Binding of fluvoxamine at the outer mouth of the channel (as suggested by Milnes et al., 2003, and Mitcheson, 2003) was expected to interfere with the transition from open to inactive (i.e., inactivation), which involves closure of an extracellular inactivation gate. This in turn was expected to antagonize terfenadine's inhibitory effects on hERG currents. However, using a molecular modeling approach, fluvoxamine was recently docked into the hERG channel, so that its protonated nitrogen binds below the Phe656 residues and outside the central cavity, which permits the trifluoromethyl group of the compound to interact with the nonaromatic binding site formed by Thr623 and Ser624   FIG. 4 . Envelope of tails protocol used to study the time dependence of hERG current block induced by terfenadine, chlorobutanol, and the combination. The voltage protocol is shown above. (A) Representative current traces evoked by an envelope of tails protocol under control conditions (control, left traces) and in the presence of 27.7nM terfenadine (upper traces), 7.4mM chlorobutanol (middle traces), and the combination of 13.8nM terfenadine and 3.7mM chlorobutanol (lower traces). Arrows indicate zero current levels. (B) Mean data (± SE) for fractional block of hERG currents by 27.7nM terfenadine, 7.4mM chlorobutanol, and the combination of 13.8nM terfenadine and 3.7mM chlorobutanol plotted as a function of the depolarizing pulse durations. Block developed mono-exponentially for both the chlorobutanol and the terfenadine and chlorobutanol combination. The number of experiments was 11 for terfenadine, 7 for chlorobutanol, and 10 for the combination.
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FRIEMEL AND ZÜ NKLER (Stansfeld et al., 2007) . This model suggests overlapping binding sites for fluvoxamine and terfenadine. The observation that the simultaneous administration of terfenadine and fluvoxamine has additive inhibitory effects on hERG peak tail currents may be compatible with both models. Further studies are necessary for the elucidation of the fluvoxamine-binding site on hERG channels.
Recently, Margulis and Sorota (2008) found that cisapride with a binding site located within the central cavity has additive inhibitory effects on hERG currents when combined with (1) quinidine with an overlapping binding site, (2) fluvoxamine, and (3) the ergtoxin BeKm-1. Whereas the first two interactions correspond to those obtained in the present study, the third does not. At low concentrations, terfenadine and CnErg1 administered in combination had subadditive inhibitory effects on hERG peak tail currents (Table 2 ). In order to examine the interaction between terfenadine and CnErg1 in detail and to calculate a CI-Fa plot, hERG currents were preblocked by one test substance and the other test substance was administered at increasing concentrations in the presence of the first test substance. When CnErg1 was administered in the presence of terfenadine, the calculated CI values were between 0.83 and 1.13, indicating a nearly additive effect of a combination of test substances according to the Chou (2006) criteria. However, when terfenadine was administered in the presence of CnErg1, the calculated CI values were between 1.20 and 1.46, indicating a moderate antagonism of two test substances applied in combination according to the Chou (2006) criteria. In summary, the interactions of terfenadine and CnErg1 at hERG channels seem to be complex and cannot be described simply by additive effects of two test substances. The observations may indicate that CnErg1 slightly antagonizes the inhibitory effects of terfenadine on hERG peak tail currents.
The simultaneous administration of terfenadine and chlorobutanol induced superadditive inhibitory effects on hERG peak tail currents (Fig. 1, Table 2 ). The observation that synergism increased at increasing test concentrations of the combination can be explained by the higher probability that both molecules bind simultaneously to the same channel at higher test concentrations. Chlorobutanol and terfenadine enhanced the inhibitory effects of the other substance concentration dependently (Fig. 2) .
Experiments studying the voltage-and time-dependent inhibitory effects of terfenadine and chlorobutanol on hERG currents demonstrated that they have different mechanisms of action and, consequently, different binding sites on hERG FIG. 5 . Long step pulse protocol used to study the time dependence of hERG current block induced by terfenadine, chlorobutanol, and the combination of terfenadine and chlorobutanol. The voltage protocol is shown above. (A) Representative recordings of current traces prior to and immediately after application of 27.7nM terfenadine (upper traces), 7.4mM chlorobutanol (middle traces), and the combination of 13.8nM terfenadine and 3.7mM chlorobutanol (lower traces). Arrows indicate zero current levels. (B) Mean data (± SE) for the development of hERG current block induced by 27.7nM terfenadine, 7.4mM chlorobutanol, and the combination of 13.8nM terfenadine and 3.7mM chlorobutanol. Block developed mono-exponentially for both the chlorobutanol and the terfenadine and chlorobutanol combination, whereas block development for terfenadine was linear with time. The number of experiments was six for terfenadine, five for chlorobutanol, and seven for the combination.
INTERACTIONS AT hERG CHANNELS 353 channels. hERG channel blockade by terfenadine showed weak voltage dependence (Fig. 3) , did not increase with depolarizing pulses > 200-ms duration during the envelope of tails protocol (Fig. 4) , and increased only slightly during the long step pulse protocol (Fig. 5) . The observation that the inhibitory effect of terfenadine on hERG currents is very slowly reversed on drug washout (Fig. 6) , an observation also made recently by Stork et al. (2007) , might be explained by a tight binding of terfenadine to the inactivated state (Perrin et al., 2008) and a slow dissociation from the open state of the hERG channel (Stork et al., 2007) . In contrast to terfenadine, voltage dependence of the chlorobutanol effects coincided with the membrane potential range over which hERG channel opening occurs (Fig. 3) . The results of the envelope of tails protocol indicate that channel opening is necessary for hERG current block by chlorobutanol (Fig. 4) , and the block developed mono-exponentially during the long step pulse protocol (Fig. 5) . These observations indicate that chlorobutanol blocks hERG channels primarily in the open state. Chlorobutanol also increased the hERG current amplitude in a membrane potential range close to the threshold of channel activation (Fig.  3B) , i.e., it had an agonistic effect at this membrane potential range. This effect might be due to chlorobutanol-induced modification of the activation-gating process of the hERG channel. The observation that coapplication of terfenadine markedly slowed the reversibility of the effects of chlorobutanol (Fig. 6 ) might indicate that the slow dissociation of chlorobutanol in the presence of terfenadine is responsible for the synergistic effects on hERG peak tail currents (Figs. 1 and 2, Table 2 ).
The binding site of chlorobutanol on hERG channels is not known. It might be suggested that hERG current block by chlorobutanol is caused by a modification of the composition of membrane lipids. Hydroxypropyl b-cyclodextrins, which are cyclic oligosaccharides used to enhance drug solubility, inhibit hERG currents at a concentration of 6%; cyclodextrins modify the lipid environment and cholesterol composition of the plasma membrane, and it has been suggested that channels that are located in the lipid raft domains tend to be sensitive to the interaction with cyclodextrins (Mikhail et al., 2007) . However, the concentration-dependent enhancement of chlorobutanol's inhibitory effects by terfenadine (Fig. 2) seems to argue against nonspecific effects of chlorobutanol on hERG channels mediated via a modification of the composition of membrane lipids and might point toward a specific binding site of chlorobutanol on hERG channels. Two observations seem to indicate a binding site for chlorobutanol on the extracellular side of the hERG channel: first, intracellular application of chlorobutanol had no effects on hERG currents, which argues against a binding site accessible via the lipid phase of the plasma membrane; second, the effects of chlorobutanol on hERG currents were rapidly reversible on washout (Fig. 6) . Further studies using mutagenesis approaches are required to characterize the chlorobutanol-binding site on hERG channels.
Chlorobutanol is used in parenteral dosage forms as an antimicrobial preservative at concentrations of up to 0.5% (about 30mM). Plasma concentrations of about 0.5mM chlorobutanol were reported in a patient receiving iv morphine preserved with 0.5% chlorobutanol (DeChristoforo et al., 1983) . The ratio of the IC 50 value for the block of hERG currents (7.4mM) to the plasma concentration of chlorobutanol is about 15 and, therefore, below the margin of 30, which seems to be the line of demarcation between substances associated with TdP and those which are not (Redfern et al., 2003) . However, the torsadogenic potential induced by block of hERG currents can be counterbalanced by effects on other types of cardiac ion channels (e.g., Na þ and L-type Ca 2þ channels; Redfern et al., 2003) . Further in vitro and in vivo electrophysiological studies are required to test the torsadogenic potential of chlorobutanol. Depending on both the site and the speed of injection, it is not unlikely that the concentration of chlorobutanol in the heart may approach the level (2.5mM) at which synergistic inhibitory effects on hERG currents were observed after simultaneous administration of increasing terfenadine concentrations (Fig. 2B) .
In conclusion, it is shown in the present study that terfenadine, which binds to the central cavity of the hERG channel, does not interact with a substance with an overlapping binding site (dofetilide) or with a substance with an unknown binding site (fluvoxamine). Its inhibitory effects are slightly antagonized by the presence of a substance binding at the outer mouth (CnErg1). Terfenadine and the preservative chlorobutanol synergistically inhibit hERG peak tail currents. It is not unlikely that similar synergistic effects on hERG currents are generated by interaction between chlorobutanol, which may be an open state blocker FIG. 6 . Time course of the development and recovery of hERG peak tail current block induced by terfenadine, chlorobutanol, and the combination obtained in three representative experiments. Bars indicate the duration of application of 27.7nM terfenadine, 7.4mM chlorobutanol, and the combination of 13.8nM terfenadine and 3.7mM chlorobutanol.
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